-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RCT-1100 in Primary Ciliary Dyskinesia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RCT-1100 in Primary Ciliary Dyskinesia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RCT-1100 in Primary Ciliary Dyskinesia Drug Details: Oligonucleotide is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RCT-2100 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RCT-2100 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RCT-2100 in Cystic Fibrosis Drug Details: RCT-2100 is under development for the...
-
Product Insights
Primary Ciliary Dyskinesia – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Ciliary Dyskinesia - Drugs In Development, 2023’, provides an overview of the Primary Ciliary Dyskinesia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Ciliary Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Cystic Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cystic Fibrosis - Drugs In Development, 2023’, provides an overview of the Cystic Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARX-720 in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARX-720 in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ARX-720 in Congestive Heart Failure (Heart Failure) Drug Details:ARX-720 is...
-
Track & Monitor
Venture Capital Investments Q3 2023
GlobalData's Venture Capital Investments report provides detailed coverage of the global venture capital investment activity across sectors in Q3 2023, covering key insights and trends.
-
Company Profile
SmarTone Telecommunications Holdings Ltd – Company Profile
SmarTone Telecommunications Holdings Ltd (SmarTone), a subsidiary of Sun Hung Kai Properties Ltd, is a provider of voice, multimedia and mobile broadband services. The company provides mobile internet, roaming services, managed solutions, and cybersecurity solutions, voice and fixed-fiber broadband services, and handsets and accessories. It also offers enterprise mobility solutions, mobile recoding, SmarTone Cloud, and Smart messaging solutions, and other value-added services. The company markets its products and services under Birdie and SmartTone brand names. It serves construction, hospitality, retail,...
Add to Basket -
Product Insights
Net Present Value Model: ARX-720
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model ARX-720 Drug Details ARX-720 is under...
-
Product Insights
Net Present Value Model: Pegbelfermin
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Pegbelfermin Drug Details Pegbelfermin (BMS-986036, PEG-FGF21,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ARX-720
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ARX-720 Drug Details ARX-720 is under development for the treatment of heart failure. The...